The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.

The disclosure provides genetically engineered microorganisms capable of producing antigen-binding molecules. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from undesirable products towards products, and optionally co-products, of interest. Further, the disclosure enables co-production of useful chemicals from gaseous substrates.

The inventive technology relates to novel paratransgenic strategies for the biocontrol of pathogens in animal systems using interfering RNA molecules expressed in genetically modified bacteria that may be configured to colonize a target host. In one preferred embodiment, the invention includes novel paratransgenic strategies for the biocontrol of pathogens in aquatic organisms raised in aquaculture environments.

The present invention discloses a method for assessing the capacity of a substance to treat or prevent hepadnavirus infection. A reporter virus carrying genetic information for a first fragment of a recombinase and a reporter cell expressing a second fragment of the recombinase are used. When the reporter virus infects the reporter cell, the two fragments of the recombinase associate and excise a stop cassette that is flanked by two recombination sites and blocks the expression of a reporter gene. Accordingly, the present invention relates to a method of assessing the capacity of a substance to treat or prevent hepadnavirus infection, a hepadnavirus comprising a nucleic acid encoding a first fragment of a recombinase and a mammalian hepatocyte or hepatoma cell comprising a nucleic acid encoding a second fragment of a recombinase and a nucleic acid comprising a stop cassette flanked by two recombination sites fused to a reporter gene.

The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.

The invention pertains to novel methods to increase the tolerance of microbial host cells to toxic substance, for example terpenes and alcohols and other membrane disrupting substances, as well as modified organism with such an increased tolerance a compared to the unmodified organism.

The invention pertains to novel methods to increase the tolerance of microbial host cells to toxic substance, for example terpenes and alcohols and other membrane disrupting substances, as well as modified organism with such an increased tolerance a compared to the unmodified organism.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

Conditionally replicating recombinant cells, compositions and vaccines having the cells, and methods of using the cells, are provided.

Conditionally replicating recombinant cells, compositions and vaccines having the cells, and methods of using the cells, are provided.